These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 3504236

  • 1. The effect of single and repeated administration of bromocriptine on monoamine metabolism in rat brain and [3H]spiroperidol binding to striatal membranes.
    Muradas V, Bazan E, Gervas JJ, Mena MA, de Yebenes JG.
    Mov Disord; 1986; 1(2):103-12. PubMed ID: 3504236
    [Abstract] [Full Text] [Related]

  • 2. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 3. Postsynaptic location of acrylamide-induced modulation of striatal 3H-spiroperidol binding.
    Hong JS, Tilson HA, Agrawal AK, Karoum F, Bondy SC.
    Neurotoxicology; 1982 Jul; 3(1):108-12. PubMed ID: 6890181
    [Abstract] [Full Text] [Related]

  • 4. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP, Wooten GF.
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [Abstract] [Full Text] [Related]

  • 5. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
    Zahniser NR, Molinoff PB.
    Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
    [Abstract] [Full Text] [Related]

  • 6. Brain neurotransmitter receptor alterations in offspring of rats exposed to phenobarbital, phenytoin or their combination during pregnancy.
    Seth PK, Alleva FR, Takagi S, Yen-Koo HC, Balazs T.
    Neurotoxicology; 1987 Mar; 8(1):45-53. PubMed ID: 3031564
    [Abstract] [Full Text] [Related]

  • 7. Relative potency of dopamine agonists on autoreceptor function in various brain regions of the rat.
    Westfall TC, Naes L, Paul C.
    J Pharmacol Exp Ther; 1983 Jan; 224(1):199-205. PubMed ID: 6848743
    [Abstract] [Full Text] [Related]

  • 8. Effects of verapamil on the release of different neurotransmitters.
    Sitges M, Reyes A.
    J Neurosci Res; 1995 Apr 01; 40(5):613-21. PubMed ID: 7602614
    [Abstract] [Full Text] [Related]

  • 9. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA, Marsh CL.
    Mol Pharmacol; 1984 Nov 01; 26(3):439-51. PubMed ID: 6238230
    [Abstract] [Full Text] [Related]

  • 10. Subsensitivity of the rat striatal dopaminergic system after treatment with bromocriptine: effects on [3H]spiperone binding and dopamine-stimulated cyclic AMP formation.
    Quik M, Iversen LL.
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Sep 01; 304(2):141-5. PubMed ID: 212684
    [Abstract] [Full Text] [Related]

  • 11. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E, Tonello C, Imhof R, Scherschlicht R, da Prada M, Carruba MO.
    J Pharmacol Exp Ther; 1993 Jul 01; 266(1):97-105. PubMed ID: 8101225
    [Abstract] [Full Text] [Related]

  • 12. [Effect of in vitro serotonin on dopaminergic binding sites in rat striatal membranes].
    Oelssner W, Raubach KH, Oelssner W.
    Biomed Biochim Acta; 1983 Jul 01; 42(7-8):931-6. PubMed ID: 6651809
    [Abstract] [Full Text] [Related]

  • 13. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM, Matvienko OA, Nurk AM.
    Biull Eksp Biol Med; 1984 Oct 01; 98(10):444-6. PubMed ID: 6541951
    [Abstract] [Full Text] [Related]

  • 14. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L, Gobert A.
    J Pharmacol Exp Ther; 1997 Jul 01; 282(1):132-47. PubMed ID: 9223549
    [Abstract] [Full Text] [Related]

  • 15. Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site.
    Levant B, Moehlenkamp JD, Morgan KA, Leonard NL, Cheng CC.
    J Pharmacol Exp Ther; 1996 Jul 01; 278(1):145-53. PubMed ID: 8764345
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Evidence for an irreversible interaction of bromocryptine with central dopamine receptors.
    Bannon MJ, Grace AA, Bunney BS, Roth RH.
    Naunyn Schmiedebergs Arch Pharmacol; 1980 May 01; 312(1):37-41. PubMed ID: 6104795
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism.
    Markstein R, Herrling PL.
    J Neurochem; 1978 Nov 01; 31(5):1163-72. PubMed ID: 702165
    [No Abstract] [Full Text] [Related]

  • 20. Bromocriptine-induced changes in dopamine and gamma aminobutyric acid in haloperidol withdrawn rats.
    Rastogi RB, Rastogi SK, Lapierre YD, Singhal RL.
    Prog Neuropsychopharmacol Biol Psychiatry; 1982 Nov 01; 6(4-6):443-7. PubMed ID: 6891811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.